INmune Bio, Inc.
INMB
Rank in Stocks
#24676
INmune Bio, Inc. is a clinical-stage biotechnology company focused on... INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Share Price
$1.13
Last synced: 2026-11-09
Market Cap
$31.36M
Change (1 day)
0.00%
Change (1 year)
-25.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade INmune Bio, Inc. (INMB)
Category
Healthcare
EPS for INmune Bio, Inc. (INMB)
EPS as of September 2026 TTM: $-0.62
According to INmune Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-0.62. At the end of 2025 the company had an EPS of $-1.86, an increase over its 2024 EPS of $-2.11.
EPS history for INmune Bio, Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.62 | -66.67% |
| 2025 | $-1.86 | -11.85% |
| 2024 | $-2.11 | 26.35% |
| 2023 | $-1.67 | 9.87% |
| 2022 | $-1.52 | -19.15% |
| 2021 | $-1.88 | 86.14% |
| 2020 | $-1.01 | 13.48% |
| 2019 | $-0.89 | -19.82% |
| 2018 | $-1.11 | 1,397.98% |
| 2017 | $-0.07 | 36.72% |
| 2016 | $-0.05 | 453.06% |
| 2015 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,625.81% |
US
|
|
| $-7.07 | 1,040.32% |
US
|
|
| $-5.29 | 753.23% |
AU
|
|
| $12.88 | -2,177.44% |
BE
|
|
| $21.56 | -3,577.42% |
NL
|
Questions about INmune Bio, Inc.'s earnings per share (EPS)
What is INmune Bio, Inc.'s earnings per share (EPS)?
INmune Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-0.62, as of Sep 2026.
What was INmune Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, INmune Bio, Inc.'s earnings per share (EPS) was $-1.86, compared with $-2.11 in 2024.
How has INmune Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, INmune Bio, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.01) and lowest in 2024 ($-2.11).
How does INmune Bio, Inc.'s earnings per share (EPS) compare with similar companies?
INmune Bio, Inc.'s earnings per share (EPS) ($-0.62) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.